

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 September 2022 (22.09.2022)



(10) International Publication Number
WO 2022/194399 A1

(51) International Patent Classification:

C07D 498/10 (2006.01) A61P 11/00 (2006.01)
C07D 498/14 (2006.01) A61K 31/395 (2006.01)
C07D 498/04 (2006.01) C07K 5/02 (2006.01)

(21) International Application Number:

PCT/EP2021/069292

(22) International Filing Date:

12 July 2021 (12.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2021/056724

16 March 2021 (16.03.2021) EP

(71) Applicant: **IDORSIA PHARMACEUTICALS LTD**
[CH/CH]; Hegenheimermattweg 91, 4123 Allschwil (CH).

(72) Inventors: **BOLLI, Martin**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **BROTSCHI, Christine**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **COM-MANDEUR, Malgorzata**; c/o Mercachem B.V. Kerkenbos 1013, 6546 Nijmegen BB (NL). **GATFIELD, John**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **KIMMERLIN, Thierry**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **SIENDT, Hervé**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **SPRINGER, Jasper**; Schimmelpennincksingel 76, 7431 Diepenveen ZN (NL). **WAGNER, Clemens**; c/o Mercachem B.V. Kerkenbos 1013, 6546 Nijmegen BB (NL). **WEGERT, Anita**; c/o Mercachem B.V. Kerkenbos 1013, 6546 Nijmegen BB (NL). **WILLIAMS, Jodi T.**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH).

(74) Agent: **VELKER, Jörg**; Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: MACROCYCLES AS CFTR MODULATORS



(57) Abstract: The present invention relates to macrocyclic compounds of Formula (I) wherein Ar¹, Ar², R¹, R², R³, R⁴, and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as modulators of CFTR.

WO 2022/194399 A1